Quantcast

Latest Imatinib Stories

2009-12-07 18:45:30

Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug.

2009-12-05 10:00:00

Omacetaxine launches different attack on CML that is impervious to other therapies.

2009-12-01 06:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc.

2009-11-13 09:54:15

One difficulty with fighting cancer cells is that they are similar in many respects to the body's stem cells.

2009-10-20 00:15:00

EAST HANOVER, N.J., Oct. 20 /PRNewswire/ -- Novartis announced today that Tasigna® (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec® (imatinib mesylate) tablets*.

2009-10-18 08:38:21

Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive.

2009-10-07 09:49:27

Phase 2 study results of targeted therapy added to chemo.

2009-10-01 04:00:00

NEW YORK, Oct. 1 /PRNewswire-USNewswire/ -- The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition.

2009-09-30 11:01:23

In new research published in the open-access, peer-reviewed scientific journal PLoS ONE, Dr Patrice Dubreuil and colleagues characterize the pharmacological profile of masitinib (AB1010), a novel tyrosine kinase inhibitor (TKI) that targets the stem cell factor (KIT), PDGFR and Lyn.


Word of the Day
logocentrism
  • The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.
The word 'logocentrism' is a blend of logo- +‎ centrism.
Related